United Financial Group

Investing with us,
you create the future

“Someone is sitting in the shade today because
someone planted a tree a long time ago“ - Warren Buffett

About company

The year of foundation of the Company

2019

Launch of the first product on the market

2020

Payment of the first dividends

2021

Countries of the project participants

48

Company's mission:

  • To bring to the market the oncology treatment drug.
  • An affordable treatment for everyone.
  • A safe therapy.

Investor

Investments

Investments in a promising business with a turnover of more than $ 200 billion dollars a year

Possibility

An opportunity to have access to all preparations and company developments at the lowest prices

Dividends

The annual payment of dividends to investors of the company, after calculating the annual profit

Inheritance

The ability to transfer their shares in the company by inheritance

Importance

Participation in the creation of an important area in the safe therapy and treatment of many diseases

Business

Profit from all development and investment tools of the company

Perspectives

Why is it profitable to invest in new
technologies and developments?

Uber

in 2010, the company's share was worth $ 0.009, and after 9 years the price rose to $ 44 per share. An investment of $ 100 in Uber, after 9 years made a profit of $ 500,000

Google

The company was founded in 1996. Initial investment in the company amounted to $ 25 million. The current capitalization of the company is about 1 trillion dollars. An investment of $ 100 in 1998 grew to $ 4,000,000 after 20 years.

Apple

Steve Jobs, Steve Wozniak, and Ron Wayne founded the company in 1976. Ron Wayne sold his 10% stake for $ 800 in 2 weeks. Today 10% of the company costs about $ 100 billion!

Alibaba

The company was founded in 1999. Attracted investments of $ 25,000,000. At the beginning of 2020, market capitalization exceeded $ 600 billion. $ 100 of investments grew to $ 2.4 million

Today, all these companies are popular and
famous, but few years ago few believed that
they had a future, for this very reason,
the shares of these companies were cheap.

Market volume

Demand for drug development

Pfizer Acquires Campto for $ 620 Million

Sanofi-Synthelabo announced that it has signed an agreement with Pfizer Inc. regarding the divestment of Aventis’ interests in Campto (irinotecan) in response to requests made by the competition authorities.Subject to the success of Sanofi-Synthelabo’s offer for Aventis, Pfizer will take over clinical studies for Campto that are currently conducted by Aventis, together with certain patents and other assets pertaining to territories where Pfizer currently markets irinotecan. The consideration for the whole transaction is of $620 million.


Source

Read moreHidde

GSK reaches an agreement to acquire TESARO, a biopharmaceutical oncology company

GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) today announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire TESARO, an oncology-focused company based in Waltham, Massachusetts, for an aggregate cash consideration of approximately $5.1 billion (£4.0 billion). The proposed transaction will significantly strengthen GSK’s pharmaceutical business, accelerating the build of GSK’s pipeline and commercial capability in oncology.


Source
Read moreHidde

Pfizer buys cancer drug maker Array BioPharma

NEW YORK & BOULDER, Colo.--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and Array BioPharma Inc. (NASDAQ: ARRY) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need. Pfizer has agreed to acquire Array for $48 per share in cash, for a total enterprise value of approximately $11.4 billion. The Boards of Directors of both companies have approved the merger.


Source

Read moreHidde

Pfizer Offers $ 14 Billion For Medivation Oncology Manufacturer

Pfizer Inc. (NYSE:PFE) and Medivation, Inc. (NASDAQ:MDVN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Medivation, a biopharmaceutical company focused on developing and commercializing small molecules for oncology, for $81.50 a share in cash for a total enterprise value of approximately $14 billion.


Source
Read moreHidde
Company Rx Sales
mlrd
 R&D spend
mlrd
1.
Phizer
New York, New York, www.phizer.com
$45.302 $7.962
2.
Roche
Basel, Switzerland, www.roche.com
$44.552 $9.803
3.
Novartis
Basel, Switzerland, www.novartis.com
 $43.481 $8.154
4.
Johnson & Johnson
New Brunswick, New Jersey, www.jnj.com
$38.815 $8.446
5.
Merck & Co.
Kenilworth, New Jersey, www.merck.com
$37.353 $7.908
6.
Sanofi
Paris, France, www.sanofi.com
 $35.121 $6.227
7.
Abbvie
North Chicago, Illinois, www.abbvie.com
 $32.067 $5.093
8.
GlaxoSmithKline
Brentford, England, www.gsk.com
 $30.645 $4.987
9.
Amgen
Thousand Oaks, California, www.amgen.com
 $22.533 $3.657
10.
Gilead Science
Foster City, California, www.gilead.com
 $21.677 $3.897
The table is reprinted from the resource Pharmexec.com, the original table here

FRAN

In 2004 – preclinical trials.
In 2006 - 2007 – clinical trials of the first and second phase.
In 2015 – development of a suppository, a new formula of the drug named FRAN.

The main advantages of the drug «FRAN» are:

What is the difference between FRAN and existing drugs?
The common properties of all chemotherapeutic drugs are high toxicity and a complete lack of selectivity of action, when the drug acts equally on healthy cells of the body and on cancer cells.

The advantage of our project is the uniqueness of the drug. Unlike all other antitumor drugs, FRAN is an absolutely safe drug of natural origin and it does not contain chemical modifiers. This fact determines the unique therapeutic properties of the drug, which will create a very high demand for it in the future.

Research, as well as the opinion of practicing oncologists, suggests that the combination of positive properties makes it unique, without worthy competitors in the antitumor market. This is proved by preclinical trials, clinical trials and more than 500 people who have already been treated with FRAN.

By the sum of the positive qualities combining high antitumor efficacy, absolute selectivity towards tumor cells and complete absence of toxicity, the drug FRAN is unique in comparison with the well-known chemotherapeutic drugs.

The development of the drug FRAN is a revolutionary solution and it opens up a new direction in the science of creating drugs for the safe treatment of cancer and, which is important, it carries out prophylaxis to restore immunity in order to destroy cancer cells at an early stage.

Already, the drug can be ordered by contacting our representatives on our website ufgroup.pro

Close

Yllo blockchain One

Yllo Messenger is a mobile application for instant messaging, crypto assets and business. Decentralized messenger built on cluster architecture. It does not have a central server. In addition to ordinary communication, it has a built-in crypto wallet for storing and transferring various cryptocurrencies

Crypto platform. On the Yllo platform you can issue any digital asset: with a unique name, logo and rules. The issuer himself sets the parameters of the total emission, inflation, burning, commission, distribution, initial price and any other properties of the asset.

Branding. Any element of the platform (instant messenger, notes, wallet for PC) can be branded as a client, as a personal tool based on Yllo.

Cryptocurrency exchange XLT.One - is a platform for the exchange of classic cryptocurrencies and all crypto assets created in Yllo.

Install the Yllo app for Apple

Website

Close